Czech Innovation Against Alzheimer’s: H2 Global Group Enters a Key Phase of Growth
The company has developed a functional prototype of a medical device for controlled hydrogen therapy in patients with mild cognitive impairment (MCI), a condition that often precedes Alzheimer’s disease. The device is non-invasive, suitable for both clinical settings and home use, and is based on a patented method developed by a Japanese research team led by Professor Shigeo Ohta, who is also a co-owner of H2 Global Group. Research results indicate that molecular hydrogen may play a crucial role in protecting brain cells, slowing inflammatory processes, and supporting metabolism and neuronal connectivity.
“Hydrogen is the smallest molecule in the universe, yet it has enormous potential to protect what is most valuable to us – our memories and independence,” explains Professor Ohta.
Group founder David Maršálek, who has been engaged in hydrogen research and commercialization since 2011, adds:
“Our goal is to bring the world’s first hydrogen-based medical device for the prevention and supportive treatment of Alzheimer’s dementia to market as quickly as possible. I am convinced that the combination of scientific evidence, patent protection, and an experienced team will enable us to confirm our position as a global leader.”
Between 2021 and 2025, H2 Global Group successfully completed its Seed stage, raising approximately CZK 360 million from investors, building a network of more than 20,000 end customers and over 50 B2B partners, and achieving revenues exceeding CZK 150 million. Based on recent transactions involving the minority shareholder H2 Founders 1, the group’s valuation is currently estimated at CZK 1.5 billion.
The company is now entering a key Series A funding round, aiming to raise USD 25–30 million. These funds will be used to finance global expansion across European, U.S., Middle Eastern, and African markets, complete clinical trials, and obtain regulatory approval in both the EU and the United States. Financial projections anticipate revenue growth from USD 3.5 million in 2025 to nearly USD 48 million by 2029.
A Broad Portfolio Beyond Medical Devices
The group’s portfolio is not limited to medical devices alone. Through H2 Medical Technologies, a manufacturer of hydrogen generators, the company supplies solutions to spa and wellness facilities, sports clubs, physiotherapy centers, and dental clinics. Their use has also been approved by the State Institute for Drug Control (ÚSKVBL) for veterinary practice, and the group is currently developing specialized applications in this area.
At the same time, the subsidiary H2 Pharm develops, manufactures, and actively markets a range of products, including H2 Premium Water®, dietary supplements such as H2 Brain® and H2 Forte®, as well as the successful cosmetic product H2 Dent Care®. These products are commercially available and represent a significant share of the group’s revenues. Distribution is handled through the company’s own e-shop and a network of B2B partners.
International Recognition and Media Impact
The success at LSI Europe 2025 confirmed that H2 Global Group holds a strong position not only in the Czech Republic but also on the global stage. Presentations delivered to hundreds of investors and industry experts opened the door to new partnerships and strategic discussions with investment funds and technology companies.
Beyond innovation, the company emphasizes a strong commitment to social responsibility. Its mission is to contribute to addressing one of today’s greatest challenges – population aging and the growing burden of neurodegenerative diseases.
“Our mission is to deliver solutions that improve the quality of life for millions of people worldwide and bring relief to their families and caregivers,” emphasizes David Maršálek.
“Opportunities like this do not come often. When people one day read about us in textbooks, our investors will be able to say: I was there. We are playing a role in a revolution where hydrogen is not only a source of energy, but also a molecule of life that connects the world,” he concludes.
More information and investor materials are available at:
www.H2Global.group
Media Coverage and Distribution
The success at LSI Europe 2025 was accompanied by exceptional media coverage. The press release announcing our progress was published on, among others:
Protext.cz
Barrandov.tv
Buzzstore.cz
Ceskenoviny.cz
Cesko247.cz
EkoNews.cz
Hrot24.cz
i60.cz
i-Lifestyle.cz
Media24.cz
MediaLive.cz
MediaToday.cz
Metro.cz
NewsRadar.cz
Protext.sk
SvetHospodarstvi.cz
WN24.cz
ZpravyTed.cz
At present, our announcement is featured among the main headlines on the ČTK (Czech News Agency) homepage.
Distribution was carried out through:
-
a backup transmission to approximately 20 major media outlets,
-
900 journalists, corporate and institutional representatives via the ČTK Infobank,
-
the Protext email service, reaching up to 6,000 recipients,
-
ČTK mobile applications, news aggregators, and online portals,
-
subscribers to monitoring services Newton Media, Mediaboard, and TOXIN.
This extensive reach further underscores the growing international interest in our work and our upcoming global expansion.
Experience the Hydrogen Revolution
Shop now on our e-shop and experience the hydrogen revolution in your own life!
🌐 www.H2Vibe.cz
🌐 www.H2Global.group
🌐 www.H2Invest.cz